Shots:
- THX has granted Biocodex an exclusive global license to develop & commercialize Batten-1 for juvenile Batten disease (CLN3), along with exclusive US & Canada rights to develop & commercialize TX01 for Gaucher & Niemann-Pick type C disease
- As per the deal, THX will lead clinical development with financial & scientific support from Biocodex, which will handle compassionate access, market access, & commercialization in licensed territories, while THX may receive ~€173M ($205.4M), incl. €12M ($14.2M) upfront, & ~€161M ($191.1M) in milestones, as well as double-digit tiered royalties on net sales
- Batten-1 is preparing to enter P-III in 2026, targeting a potential launch by 2030, while TX01 is an adapted oral formulation of an already approved active substance
Ref: Businesswire | Image: THX & Biocodex |Press Release
Related News: Insilico Medicine and CMS Enter Multiple Collaborations to Advance Therapeutics in CNS and Autoimmune Indications
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
